Contains An Albumin Patents (Class 435/407)
  • Patent number: 11371019
    Abstract: A population of early-stage burst-forming unit-eryhtoid (BFU-E) cells characterized by low expression of the Type III Transforming Growth Factor ? Receptor (TGFRPIII) and uses thereof for producing red blood cells in vitro, genotoxicity analysis of chemicals, drug sensitivity assessment, and drug development. Also described herein are methods for producing the population of early-stage BFU-E cells and methods for producing red blood cells.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: June 28, 2022
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Harvey Lodish, Xiaofei Gao, Hsiang-Ying Lee
  • Patent number: 10273455
    Abstract: The present invention relates to a method for in vitro expansion of erythroid cells. The method includes subjecting erythroid cells to 3-dimensional packed cell culture using a porous structure. The use of the composition according to the present invention enables in vitro expansion of erythroid cells in the most efficient manner.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: April 30, 2019
    Assignee: IUCF-HYU
    Inventors: Eun Jung Baek, Eun-Mi Lee
  • Patent number: 9943545
    Abstract: The invention provides improved methods for preparing hematopoietic cells for transplantation and the resulting improved hematopoietic cell compositions. The invention further relates to improved culture media and methods of culturing, processing, modulating, and expanding blood cell products for hematopoietic transplantation.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: April 17, 2018
    Assignee: Fate Therapeutics, Inc.
    Inventor: Betsy Denise Rezner
  • Patent number: 9845482
    Abstract: Compositions and methods comprising bioenergetic agents for restoring the quality of aged oocytes, enhancing oogonial stem cells or improving derivatives thereof (e.g., cytoplasm or isolated mitochondria) for use in fertility-enhancing procedures, are described.
    Type: Grant
    Filed: April 13, 2012
    Date of Patent: December 19, 2017
    Assignees: The General Hospital Corporation, President and Fellows of Harvard College
    Inventors: Jonathan L. Tilly, David A. Sinclair
  • Patent number: 9487755
    Abstract: Albumin-supplemented and xenogeneic product-free cell culture media, cell culture media supplements, and cell culture media kits for the support of primary culture of normal non-hematopoietic cells of mesodermal origin suitable for both research and clinical applications.
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: November 8, 2016
    Inventor: David Moscatello
  • Publication number: 20150087058
    Abstract: The present invention relates to a stem cell culture medium which can be substituted for a conventional stem cell culture medium containing the heterologous protein fetal bovine serum, and more particularly to a stem cell culture medium containing a basal medium and a knockout serum replacement and a method of culturing stem cells using the same. According to the invention, a high purity of stem cells having a reduced ability to spontaneously differentiate can be obtained without having to use the heterologous protein fetal bovine serum and expensive growth factors (EGF and bFGF), and thus the efficacy of stem cell therapy can be significantly increased.
    Type: Application
    Filed: April 17, 2013
    Publication date: March 26, 2015
    Applicant: SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
    Inventor: Do Hyun Nam
  • Publication number: 20140328808
    Abstract: It is an object of the present invention to provide a culture medium for in vitro culture of a colorectal epithelial stem cell or the like, a method of in vitro culturing a colorectal epithelial stem cell or the like using the culture medium, a prophylactic or therapeutic agent for a bowel disease containing a colorectal epithelial stem cell or the like cultured by the method, a method of administrating, i.e., transplanting a colorectal epithelial stem cell or the like cultured by the method to a bowel disease patient, and a method of isolating a colorectal epithelial stem cell or the like. The culture medium for in vitro culture of a colorectal epithelial stem cell and/or a colorectal epithelial cell characteristically contains serum albumin, Wnt3a, and r-spondin-1.
    Type: Application
    Filed: October 26, 2012
    Publication date: November 6, 2014
    Applicant: National University Corporation Tokyo Medical and Dental University
    Inventors: Mamoru Watanabe, Tetsuya Nakamura
  • Publication number: 20140234966
    Abstract: The invention relates to a new formulation of albumin, a method for producing the albumin formulation and to uses of the albumin formulation, for example in cell culture such as mammalian cell culture and particularly in stem cell culture.
    Type: Application
    Filed: July 5, 2012
    Publication date: August 21, 2014
    Applicant: NOVOZYMES BIOPHARMA DK A/S
    Inventors: Sandra Marie Merkel, Luke Dimasi, Collette Ann Sheahan, Philip Harvey Morton
  • Patent number: 8796025
    Abstract: The invention is directed to methods for the treatment of wounds. Such methods utilize novel compositions, including but not limited to amnion-derived multipotent cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine suspension or ACCS), cell lysates derived therefrom, cell products derived therefrom, each alone or in combination.
    Type: Grant
    Filed: May 8, 2012
    Date of Patent: August 5, 2014
    Assignee: Stemnion, Inc.
    Inventors: Charlotte A Emig, Catherine J Trumpower, Vivienne S Marshall
  • Patent number: 8790923
    Abstract: Viable progenitor cells are extracted from frozen umbilical cord tissue. In embodiments, the umbilical cord tissue is a blood vessel bearing perivascular Wharton's jelly, and the extracted progenitor cells are HUCPVCs.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: July 29, 2014
    Inventors: Jane E. Ennis, Rahul Sarugaser, John E. Davies
  • Publication number: 20130344602
    Abstract: The present invention relates in part to methods for producing tissue-specific cells from patient samples, and to tissue-specific cells produced using these methods. Methods for reprogramming cells using RNA are disclosed. Therapeutics comprising cells produced using these methods are also disclosed.
    Type: Application
    Filed: June 28, 2013
    Publication date: December 26, 2013
    Applicant: Factor Bioscience, Inc.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 8609416
    Abstract: Compositions, and uses thereof, which are beneficial for eukaryotic cells in culture, and methods for their use in promoting cell growth, viability and recombinant protein expression. The methods disclosed in the present application are useful, for example, for improving cell viability and in accelerating the rate of cell growth of cells grown in culture. In one aspect, the supplements of the invention are useful for improving or enhancing the yield of the recombinant proteins from the cell cultures.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: December 17, 2013
    Assignee: Ventria Bioscience
    Inventor: Michael E. Barnett
  • Patent number: 8597943
    Abstract: The present invention relates to methods for the cultivation of a population of cells in a serum free cell culture medium, wherein the population of cells has a cell concentration of less than 100 cells/ml, wherein a serum free cell culture medium containing recombinant albumin and recombinant transferrin is used.
    Type: Grant
    Filed: April 9, 2010
    Date of Patent: December 3, 2013
    Assignee: CELLCA GmbH
    Inventors: Kolja Hegel, Olaf Kruger, Aziz Cayli
  • Patent number: 8475788
    Abstract: The invention is directed to methods of promoting the healing of spinal cord injury. The invention is further directed to methods of minimizing the extent of scarring following spinal cord injury. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), each alone or in combination with each other and/or other agents.
    Type: Grant
    Filed: November 27, 2007
    Date of Patent: July 2, 2013
    Assignee: Stemnion, Inc.
    Inventors: George L. Sing, Diana L. Clarke, Vivienne S. Marshall
  • Patent number: 8426203
    Abstract: Previous methods for culturing primate pluripotent stem cells have required either fibroblast feeder cells or a medium which was exposed to fibroblast feeder cells to maintain the stem cells in an undifferentiated state. It has now been found that high levels of fibroblast growth factor in a medium together with at least one of gamma aminobutyric acid, pipecolic acid, and lithium, enables pluripotent stem cells to remain undifferentiated indefinitely through multiple passages, even without feeder cells or conditioned medium. Without beta-mercaptoethanol, the medium improves cloning efficiency. Also, a matrix of human proteins can be used to culture the undifferentiated cells without exposing the cells to animal products. Further disclosed are new primate pluripotent cell lines made using the defined culture conditions, including the medium and the matrix. Such new cell lines will have never been exposed to animal cells, animal products, feeder cells or conditioned medium.
    Type: Grant
    Filed: March 22, 2012
    Date of Patent: April 23, 2013
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: James A. Thomson, Tenneille Ludwig
  • Patent number: 8338175
    Abstract: The present disclosure describes a tissue system with conjunctival cells, including conjunctival stem cells. The conjunctival tissue system is derived from isolated tissue comprising conjunctival cells, and is suitable for restoring ocular surface impairments, particularly those that result from damaged or diseased conjunctiva. The tissue system is generated using a simple single medium culture scheme, and a support material, such as human amniotic membrane. The conjunctival tissue system generate is suitable for transplantation to treat the ocular surface of an eye of a subject that is damaged or diseased.
    Type: Grant
    Filed: February 23, 2007
    Date of Patent: December 25, 2012
    Assignee: Reliance Life Sciences Pvt. Ltd.
    Inventors: Kashyap Subhadra Devi, Kishore Reddy, Viraf Vasania
  • Publication number: 20120315697
    Abstract: The present invention relates to cell culture media containing combinations of proteins, as well as methods of making the cell culture media, and methods of using the cell culture media to improve growth characteristics of cultured cells.
    Type: Application
    Filed: February 18, 2010
    Publication date: December 13, 2012
    Applicant: VENTRIA BIOSCIENCE
    Inventors: Steven Clyde Pettit, Mary Ann Michelle Fernandez Santos, Ning Huang
  • Publication number: 20120276632
    Abstract: The present invention provides a cell culture medium supplement comprising plasma-free platelet lysate and medium supplemented with this supplement. The present invention further provides a method for preparing the supplement comprising the steps of (a) preparing platelet rich plasma; (b) removing the plasma; and (c) lysing the platelets.
    Type: Application
    Filed: May 30, 2012
    Publication date: November 1, 2012
    Applicant: MEDICAL UNIVERSITY OF GRAZ
    Inventors: Dirk Strunk, Katharina Schallmoser, Eva Rohde
  • Patent number: 8278102
    Abstract: Viable progenitor cells are extracted from frozen umbilical cord tissue. In embodiments, the umbilical cord tissue is a blood vessel bearing perivascular Wharton's jelly, and the extracted progenitor cells are HUCPVCs.
    Type: Grant
    Filed: December 21, 2006
    Date of Patent: October 2, 2012
    Inventors: Jane Ennis, Rahul Sarugaser, John E. Davies
  • Patent number: 8252590
    Abstract: The present invention relates to mammalian cell culture media which comprise supernatant from some of the fractions of human plasma fractionation according to the Cohn method, more specifically, the supernatant of fractions I and II+III. When said supernatant is added as a culture medium supplement it provides various nutrients and factors for the effective maintenance and/or proliferation of the cultured mammalian cells. In addition, the present invention relates to the preparation process and use of said medium in the culture of mammalian cells.
    Type: Grant
    Filed: July 2, 2010
    Date of Patent: August 28, 2012
    Assignee: Grifols, S.A.
    Inventors: Juan Ignacio Jorquera Nieto, Montserrat Costa Rierola, José María Diez Cervantes
  • Patent number: 8187881
    Abstract: The invention is directed to methods for the treatment of wounds. Such methods utilize novel compositions, including but not limited to amnion-derived multipotent cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine suspension or ACCS), cell lysates derived therefrom, cell products derived therefrom, each alone or in combination.
    Type: Grant
    Filed: December 1, 2009
    Date of Patent: May 29, 2012
    Assignee: Stemnion, Inc.
    Inventors: Charlotte A. Smith, Catherine J. Trumpower, Vivienne S. Marshall
  • Publication number: 20120083032
    Abstract: An embryonic stem cell line derived from a nucleus-transferred oocyte prepared by transferring a nucleus of a human somatic cell into an enucleated human oocyte may differentiate into various desired cell types.
    Type: Application
    Filed: December 9, 2011
    Publication date: April 5, 2012
    Applicant: H. BION CO., LTD.
    Inventors: Sung-Il ROH, Woo-Suk HWANG, Byeong-Chun LEE, Sung-Keun KANG, Young-June RYU, Eu-Gene LEE, Soon-Woong KIM, Dae-Kee KWON, Hee-Sun KWON, Ja-Min KOO, Eul-Soon PARK, Youn-Young HWANG, Hyun-Soo YOON, Jong-Hyuk PARK, Sun-Jong KIM
  • Publication number: 20120077271
    Abstract: Fetal blood multi-lineage progenitor cells that are capable of a wide spectrum of transdifferentiation are described, as well as methods of differentiating the progenitor cells into chondrocytes.
    Type: Application
    Filed: November 30, 2011
    Publication date: March 29, 2012
    Inventor: Daniel P. Collins
  • Patent number: 8058066
    Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.
    Type: Grant
    Filed: November 30, 2009
    Date of Patent: November 15, 2011
    Assignee: Stemnion, Inc.
    Inventors: Vivienne S. Marshall, Charlotte A. Smith, Catherine J. Trumpower, George L. Sing, Linda O. Palladino
  • Publication number: 20110262967
    Abstract: The present invention refers to the area of cell culture technology and relates to methods for multiplying/cloning cells, preferably cell lines, which are important to the production of biopharmaceuticals. The invention further relates to methods for manufacturing proteins and to the use of cells extracted and multiplied through single cell sorting and to media compositions that enable a multiplication of single cells. Through the use of albumin-producing, preferably HSA-producing, cells as feeder cells for the conditioning of medium or as host cells, the recloning efficiency and thereby the quantity of clones obtained can be significantly increased. A combination of these approaches is also possible. Through the use of albumin-producing, preferably HSA-producing, cells, an increase in the recloning efficiency can be achieved in serum-free and/or insulin-free medium as well, and in different cell types.
    Type: Application
    Filed: September 9, 2009
    Publication date: October 27, 2011
    Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
    Inventors: Lore Florin, Rebecca Bischoff, Juergen Fieder, Hitto Kaufmann, Thomas Krieg
  • Publication number: 20110229965
    Abstract: The present invention discloses a method of isolation, pooling and further culturing of Mesenchymal Stem cells (MSC) for clinical application. Present invention also discloses the method of establishing Master Cell bank, followed by Working Cell Bank from which the final therapeutic composition referred to as Investigational Product/Investigational Medicinal Product comprising of allogenic bone marrow-derived MSC is formulated for clinical applications.
    Type: Application
    Filed: November 25, 2010
    Publication date: September 22, 2011
    Inventors: Rakhi Pal, Pawan Kumar Gupta, Prasanna Kumar Kemburu, Joyothi Prasanna, Satish Totey, Raviraja Neelavar Seetharam, Umesh Baikunje Golithadka, Anish Sen Majumdar
  • Patent number: 7993917
    Abstract: Methods for the diagnosis of visceral, cutaneous and canine leishmaniasis in a subject suspected of being infected with the parasitic protozoa Leishmania is disclosed. Disclosed are antibody-capture enzyme-linked immunosorbent assays (ELISAs) for the detection of antibodies to Leishmania parasite soluble antigens and antigen-capture ELISAs for the detection of Leishmania parasite soluble antigens in host samples. Also disclosed are immunodiagnostic kits for the detection of Leishmania parasite circulating antigens or IgM and IgG antibodies in a sample from subject having visceral, cutaneous or canine leishmaniasis. In these methods and kits, detection may be done photometrically or visually. The methods and kits also allow the visualization of Leishmania amastigotes or promastigotes in a sample.
    Type: Grant
    Filed: August 20, 2009
    Date of Patent: August 9, 2011
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventor: Samuel K. Martin
  • Publication number: 20110189751
    Abstract: Compositions, and uses thereof, which are beneficial for eukaryotic cells in culture, and methods for their use in promoting cell growth, viability and recombinant protein expression. The methods disclosed in the present application are useful, for example, for improving cell viability and in accelerating the rate of cell growth of cells grown in culture. In one aspect, the supplements of the invention are useful for improving or enhancing the yield of the recombinant proteins from the cell cultures.
    Type: Application
    Filed: December 17, 2010
    Publication date: August 4, 2011
    Applicant: Ventria Bioscience
    Inventor: Michael E. Barnett
  • Patent number: 7989205
    Abstract: Albumin-supplemented and xenogeneic product-free cell culture media, cell culture media supplements, and cell culture media kits for the support of primary culture of normal non-hematopoietic cells of mesodermal origin suitable for both research and clinical applications.
    Type: Grant
    Filed: October 4, 2006
    Date of Patent: August 2, 2011
    Assignee: American Cryostem Corporation
    Inventor: David K. Moscatello
  • Patent number: 7923245
    Abstract: The present invention discloses a medium for a serum-free medium capable of culturing ES cells for a long period while maintaining their undifferentiated state without using feeder cells, and a basal medium for producing the medium thus described. The basal medium of the present invention is characterized by that it has composition shown by Table I. Further, the present invention discloses a medium for ES cells produced with the basal medium.
    Type: Grant
    Filed: December 27, 2004
    Date of Patent: April 12, 2011
    Inventors: Miho Furue, Tetsuji Okamoto, Makoto Asashima
  • Publication number: 20110076253
    Abstract: The present invention relates to compositions and methods for culturing stem cells, particularly embryonic stem cells. Specifically, the invention relates to a culture medium that supports proliferation of substantially undifferentiated stem cells, while maintaining potency of the cells. An an embodiment, the culture medium is defined and supports proliferation of substantially undifferentiated embryonic stem cells in essentially serum free and feeder cell free conditions. Compositions for making the medium and methods using the culture medium are also provided.
    Type: Application
    Filed: July 28, 2006
    Publication date: March 31, 2011
    Inventors: Michael P. Snyder, Joyce J. Lu
  • Publication number: 20110065192
    Abstract: An embryonic stem cell line derived from a nucleus-transferred oocyte prepared by transferring a nucleus of a human somatic cell into an enucleated human oocyte may differentiate into various desired cell types.
    Type: Application
    Filed: November 20, 2009
    Publication date: March 17, 2011
    Applicant: H Bion Co., Ltd.
    Inventors: Sung-II Roh, Woo-Suk Hwang, Byeong-Chun Lee, Sung-Keun Kang, Young-June Ryu, Eu-Gene Lee, Soon-Woong Kim, Dae-Kee Kwon, Hee-Sun Kwon, Ja-Min Koo, Eul-Soon Park, Youn-Young Hwang, Hyun-Soo Yoon, Jong-Hyuk Park, Sun-Jong Kim
  • Publication number: 20110008893
    Abstract: Disclosed are a medium for mammalian somatic cells with which mammalian somatic cells can be grown effectively when the mammalian somatic cells are cultured, while reducing the amount of serum to be added to the medium as much as possible or without adding serum thereto, and an additive to constitute the medium. By blending of a ligand for an endothelial cell differentiation gene (Edg) family receptor and a ligand for a serotonin receptor to a medium, somatic cells of mammals can be grown even in cases where the medium does not contain serum at all or contains only a small amount thereof.
    Type: Application
    Filed: December 26, 2008
    Publication date: January 13, 2011
    Applicant: FUJIREBIO INC.
    Inventors: Itsuro Sugimura, Yoshiyuki Hotta, Harumi Yamaguma
  • Publication number: 20100317104
    Abstract: A serum-free media composition for maintenance or directed differentiation of human embryonic stem cells (HESCs) toward particular cell lineages is disclosed. The media comprises one or more cell nutrient media, a recombinant human albumin or equivalent thereof and optionally at least one agent involved in HESC differentiation. The media composition is substantially free of any human or animal derived products.
    Type: Application
    Filed: April 8, 2010
    Publication date: December 16, 2010
    Inventors: Andrew George Elefanty, Edouard Guy Stanley, Elizabeth Siewsun Ng
  • Publication number: 20100248368
    Abstract: A process for the preparation of a composite biomaterial comprising: providing a first substantially solid component comprising one or more of collagen, a glycosaminoglycan, albumin, hyaluronan, chitosan, and synthetic polypeptides comprising a portion of the polypeptide sequence of collagen, and optionally an inorganic material, said component having at least a surface portion that is porous; providing a fluid composition comprising one or more of collagen, a glycosaminoglycan, albumin, hyaluronan, chitosan, and synthetic polypeptides comprising a portion of the polypeptide sequence of collagen, and a liquid carrier, and optionally an inorganic material; contacting said fluid composition with said porous surface portion of said first component; cooling said fluid composition to a temperature at which the liquid carrier transforms into a plurality of solid crystals or particles; removing at least some of the plurality of solid crystals or particles by sublimation and/or evaporation.
    Type: Application
    Filed: August 10, 2007
    Publication date: September 30, 2010
    Applicants: CAMBRIDGE ENTERPRISE LIMITED, MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Andrew Lynn, William Bonfield, Zachary D. Wissner-Gross, Brendan A. Harley, Ioannis V. Yannas, Lorna J. Gibson
  • Publication number: 20100184223
    Abstract: The present invention relates to a biomaterial for cell or tissue culture, based on a polymeric carrier, which contains at least one crosslinkable hydrophilic polymer. The polymer is functionalized with groups that are selected from maleimide, vinylsulfonic, acrylate, alkyl halide, azirine, pyridyl, thionitrobenzene acid groups, or arylating groups. The invention relates further to a method of production of said biomaterial, and the use of particular functionalizing groups for the production of a biomaterial for the cultivation of tissue and/or cells. The biomaterial can have biofactors that exert a particular action on cells.
    Type: Application
    Filed: January 11, 2010
    Publication date: July 22, 2010
    Inventor: Helmut Wurst
  • Publication number: 20100184221
    Abstract: The present invention provides a method for isolating cells, in particular, stem cells, which method comprises the steps of: dissociating cells from a tissue of animal origin; seeding and incubating the cells in a culture vessel with no surface treatment; and selecting cells adhered to the vessel.
    Type: Application
    Filed: January 11, 2008
    Publication date: July 22, 2010
    Applicants: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Seiichi Yokoo, Satoru Yamagami
  • Patent number: 7723106
    Abstract: A stroma-free, serum-free, and chemically defined medium and a method for mononuclear cell expansion ex vivo using the same. An exemplary medium includes a basal medium, a serum substitute, and a cytokine formula.
    Type: Grant
    Filed: July 29, 2005
    Date of Patent: May 25, 2010
    Assignee: Food Industry Research & Development Institute
    Inventors: Shiaw-Min Hwang, Chao-Ling Yao, Tzu-Bou Hsieh, I-Ming Chu
  • Publication number: 20100028940
    Abstract: The present invention relates to novel selection marker vectors, and methods for using these vectors to generate stable gene expression systems in eukaryotic cells utilizing any enzyme useful in the eukaryotic sterol/cholesterol biosynthetic pathway, such as a 3-ketosteroid reductase, as a metabolic selection marker to select transfected cells. In one embodiment, the method comprises transfecting cells that are auxotrophic for cholesterol with a vector encoding 3-ketosteroid reductase and at least one heterologous protein, and selecting cells that have the ability to survive in medium lacking cholesterol and/or producing the heterologous protein in these cells in chemically defined and/or serum-free media.
    Type: Application
    Filed: May 18, 2006
    Publication date: February 4, 2010
    Applicant: BioFactura, Inc.
    Inventors: Luis Branco, Darryl Sampey
  • Patent number: 7635589
    Abstract: The inventive method for the preparation of a dermal papilla tissue in accordance with the present invention makes it possible to form a quantity of the dermal papilla tissues having hair follicle inductive ability, and accordingly, it can be effectively used for the treatment of alopecia through cell transplantation.
    Type: Grant
    Filed: November 29, 2005
    Date of Patent: December 22, 2009
    Assignees: Lifecord Inc., Corp.
    Inventors: Jung-Keug Park, Doo-Hoon Lee, Hee-Hoon Yoon, Youn-Ho Shin, Young Jin Kim
  • Publication number: 20090305401
    Abstract: The present invention provides a cell culture medium supplement comprising plasma-free platelet lysate and medium supplemented with this supplement. The present invention further provides a method for preparing the supplement comprising the steps of (a) preparing platelet rich plasma; (b) removing the plasma; and (c) lysing the platelets.
    Type: Application
    Filed: September 17, 2007
    Publication date: December 10, 2009
    Inventors: Dirk Strunk, Katharina Schall-Moser, Eva Rohde
  • Publication number: 20090253151
    Abstract: The present invention relates to a method for obtaining master adult pluripotent stem (MAPS) cells from adult human corneal epithelial tissues. The MAPS cells are obtained on the basis of pluripotent markers. Further the invention provides MAPS cells that are capable of self renewal and differentiation and have characteristics similar to that of human embryonic stem cells. The MAPS cells also retain the ability to differentiate into cells of different lineages. The composition comprising MAPS cells are useful for therapeutic purposes. Further, the invention provides a culture medium for proliferation of MAPS cells.
    Type: Application
    Filed: August 31, 2007
    Publication date: October 8, 2009
    Applicant: STEMPEUTICS RESEARCH PRIVATE LIMITED
    Inventors: Satish Totey, Jyothi Prasanna
  • Publication number: 20090155900
    Abstract: The present invention relates to cell culture, more specifically to cell culture which may be cell culture such as stem cell culture, embryonic stem cell (ESC) culture and primary cell culture. Disclosed herein are compositions of matter, including without limitation cell matrices, matrix-forming formulations and cell cultures, wherein the cells may be cells such as stem cells, such as ESC, or primary cells, such as keratinocyte and fibroblast cells. Also disclosed herein are articles of manufacture comprising one or more of the compositions of matter of the invention, methods of making and using the compositions of matter and articles of manufacture of the invention, business methods, and tangible media comprising instructions or plans for one or more of the methods and compositions of the invention.
    Type: Application
    Filed: December 12, 2008
    Publication date: June 18, 2009
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Mohanachari Vemuri, Sackamone Phommachanh, Katherine Wagner, Mary Tilkins
  • Patent number: 7541188
    Abstract: The present invention relates to in vitro cultured skin substitutes, and in particular to improved methods for organotypic culture of skin substitutes. In some embodiments, the dermal equivalent of the skin substitute is lifted to air interface of the culture prior to seeding with keratinocytes. In other embodiments, increased concentrations of collagen are used to form the dermal equivalent. In still other embodiments, optimized media are utilized to maintain the skin equivalents.
    Type: Grant
    Filed: December 7, 2004
    Date of Patent: June 2, 2009
    Assignee: Stratatech Corporation
    Inventors: Paul Barth Conrad, Cathy Ann-Rusmussen Ivarie, Lynn Allen-Hoffmann
  • Publication number: 20090029464
    Abstract: Previous methods for culturing human embryonic stem cells have required either fibroblast feeder cells or a medium which has been exposed to fibroblast feeder cells in order to maintain the stem cells in an undifferentiated state. It has now been found that if an antagonist of bone morphogenic protein is added to the medium in which the stem cells are cultured, together with fibroblast growth factor, the stem cells will remain undifferentiated indefinitely, even without feeder cells or conditioned medium.
    Type: Application
    Filed: September 29, 2008
    Publication date: January 29, 2009
    Inventors: Ren-He Xu, James A. Thomson
  • Publication number: 20090028838
    Abstract: The present invention provides a serum-free supplement which supports the growth of hematopoietic cells in culture. Also provided are a medium comprising a basal medium supplemented with the serum-free supplement of the present invention. The present invention also provides methods for culturing and for differentiating hematopoietic cells.
    Type: Application
    Filed: August 15, 2008
    Publication date: January 29, 2009
    Applicant: INVITROGEN CORPORATION
    Inventors: John P. Daley, Barbara M. Dadey, William C. Biddle, Michelle G. Wysocki
  • Publication number: 20090017539
    Abstract: The invention provides means and methods for stem cell proliferation and subsequent generation and expansion of progenitor cells. The invention in particular provides media and other culture conditions for the same. The cells are preferably used as effector cells as clinical therapeutics.
    Type: Application
    Filed: September 28, 2006
    Publication date: January 15, 2009
    Inventor: Jan Spanholtz
  • Patent number: 7452721
    Abstract: Methods for the diagnosis of visceral, cutaneous and canine leishmaniasis in a subject suspected of being infected with the parasitic protozoa Leishmania is disclosed. Disclosed are antibody-capture enzyme-linked immunosorbent assays (ELISAs) for the detection of antibodies to Leishmania parasite soluble antigens and antigen-capture ELISAs for the detection of Leishmania parasite soluble antigens in host samples. Also disclosed are immunodiagnostic kits for the detection of Leishmania parasite circulating antigens or IgM and IgG antibodies in a sample from subject having visceral, cutaneous or canine leishmaniasis. In these methods and kits, detection may be done photometrically or visually. The methods and kits also allow the visualization of Leishmania amastigotes or promastigotes in a sample.
    Type: Grant
    Filed: November 18, 2004
    Date of Patent: November 18, 2008
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventor: Samuel K. Martin
  • Publication number: 20080199956
    Abstract: The invention relates to a method for storages of human cells in particular, cell media for storage of cells and the use of such cell media for storage of cells, wherein the vitality of the cells is preserved during the storage.
    Type: Application
    Filed: June 30, 2006
    Publication date: August 21, 2008
    Applicant: Cytonet GmbH & Co. KG
    Inventors: Lubomir Arseniev, Krassimira Alexandrova, Marc Barthold, Carsten Griesel, Hans-Gerd Heuft, Sabine Kafert-Kasting, Christoph Priesner
  • Publication number: 20080085554
    Abstract: A culture medium for preparation of feeder cells for embryonic stem cells, which can efficiently establish feeder cells for use in culture of embryonic stem cells including human's from limited donor-derived materials and culture them in a condition of a reduced risk of infection, is provided. Further, a preparation method of feeder cells, which is relatively safe even when subjected to coculture with embryonic stem cells including human's, and the resulting feeder cells therefrom are provided. With the culture medium for preparation of feeder cells for embryonic stem cells comprising at least a serum albumin and insulin in a basal medium, a cell population comprising at least one kind of cells selected from fetal skin fibroblasts, fetal myofibroblasts, fetal lung fibroblasts, fetal epithelial cells, fetal endothelial cells, adult skin fibroblasts, adult lung fibroblasts, adult epithelial cells and endothelial cells which can become feeder cells for embryonic stem cells can be stably proliferated.
    Type: Application
    Filed: February 10, 2005
    Publication date: April 10, 2008
    Inventors: Norio Nakatsuji, Hirofumi Suemori, Isao Asaka, Harafumi Sugai, Reiko Okamoto